Compare KIDS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KIDS | REPL |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.4M | 454.6M |
| IPO Year | 2016 | 2018 |
| Metric | KIDS | REPL |
|---|---|---|
| Price | $26.58 | $14.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $24.67 | $5.67 |
| AVG Volume (30 Days) | 202.4K | ★ 7.3M |
| Earning Date | 04-30-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,049,000.00 | N/A |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.95 | N/A |
| 52 Week Low | $14.42 | $1.50 |
| 52 Week High | $25.57 | $15.71 |
| Indicator | KIDS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 82.17 | 62.46 |
| Support Level | $15.61 | $7.52 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.05 | 1.56 |
| MACD | 0.36 | 0.32 |
| Stochastic Oscillator | 98.08 | 87.25 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.